(Q35982127)

11 August 2017

Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival (English)

1 reference

11 August 2017

Dixon AR

1

1 reference

11 August 2017

Robertson JF

2

1 reference

11 August 2017

Jackson L

3

1 reference

11 August 2017

Nicholson RI

4

1 reference

11 August 2017

Walker KJ

5

1 reference

11 August 2017

Blamey RW

6

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 November 1990

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

62

1 reference

11 August 2017

5

1 reference

11 August 2017

868-870

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1990.397

11 August 2017

0 references

cites work

A computer program for comparing K samples with right-censored data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971509

The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971509

The Hormonal Activity of the Postmenopausal Ovary

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971509

Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist D-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971509

Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971509

Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971509

Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland

27 July 2018

1 reference

12 December 2020

Steroid receptors in early breast cancer: value in prognosis

1 reference

12 December 2020

The endocrinological evaluation of bilateral and unilateral oophorectomy in premenopausal women

1 reference

12 December 2020

Therapeutic significance and the mechanism of action of the LH-RH agonist ICI 118630 in breast and prostate cancer

1 reference

12 December 2020

THERAPEUTIC CASTRATION VERSUS PROPHYLACTIC CASTRATION IN BREAST CANCER

1 reference

12 December 2020

A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer

1 reference

12 December 2020

Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy

1 reference

12 December 2020

Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1990.397

1 reference

Dimensions Publication ID

11 August 2017

0 references

1 reference

11 August 2017

1 reference